Form D · Other Technology
Pheast Therapeutics, Inc.
Redwood City, CA · CIK 0001943737
Offering snapshot reported Oct 16, 2025 · SEC filing
- Reported sold
- $24.6M Offering amount: $40M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 7, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 16, 2025 | Initial | $24,588,083 | No comparison | 7 | SEC filing |
| Apr 10, 2025 | Amendment | $75,250,000 | $50,025,302vs Oct 28, 2022 | 7 | SEC filing |
| Oct 28, 2022 | Initial | $25,224,698 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-560984
Source: Form D, filed Oct 16, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Amira Barkal | Director |
| Steven Gillis | Director |
| Thomas Marty | Executive |
| Roy Maute | Director, Executive |
| Raphael Rousseau | Executive |
| Jacob Vogelstein | Director |
| Irving Weissman | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
200 Cardinal Way, Ste 300
Redwood City, CA, 94063
Redwood City, CA, 94063